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Figure 1. Graph depicting the effect sizes (95% CI) for pain.
or in combination with other therapies. These data should predicate a
re-evaluation of its overall cost-utility.
541
THE IMPACT OF INTRA-ARTICULAR HYALURONIC ACID ON GAIT
VARIABILITY IN KNEE OSTEOARTHRITIS PATIENTS
J.E. DeCaria1, R. Petrella1,2, D. Wolfe1,3, B. Chesworth3,
M. Montero-Odasso1,2
1Lawson Hlth.Res. Inst., London, ON, Canada; 2The Univ. of Western Ontario,
Schulich Sch. of Med. and Dentistry, London, ON, Canada; 3The Univ. of
Western Ontario, The Faculty of Hlth.Sci., London, ON, Canada
Purpose: Our objective was to collect pilot data on the effect of intra-
articular hyaluronic acid (HA) treatment on the gait variability of knee
osteoarthritis (OA) patients. The degenerative knee changes, pain, and loss
of function associated with knee OA can lead to a less stable walking
pattern, increasing the risk for falling. Gait variability, speciﬁcally high
stride time (StrTM), single support time (SSTM), and base of support (BSup)
variability, has been shown to predict falls, and is associated with mobility
decline and disability. Intra-articular HA knee injections are used to control
pain in knee OA patients; however, evidence on the effect of HA on
spatio-temporal gait performance is limited. We hypothesized that knee
OA patients treated with HA would experience greater reductions in pain
and gait variability than matched controls receiving placebo injections (P).
Methods: Thirty older adults with mild to moderate radiographically diag-
nosed knee OA were equally randomized to receive 3 consecutive weekly
knee injections of 2 ml HA (20 mg of HA) or 1.2 ml P (0.001 mg of
HA). Fast gait characteristics were determined with a 10 metre electronic
walkway (GAITRite System), and clinical outcomes of knee pain, stiffness,
and physical function were assessed using the WOMAC OA Index. Gait
variability was determined by calculating the coeﬃcient of variation (CoV)
for each of StrTM, SSTM, and BSupp. Treatment effects were determined
by comparing baseline outcomes to those three (3m) and six months (6m)
post-treatment, using repeated measures ANCOVA, controlling for baseline
fear of falling.
Results: The participants were [Mx (SD)] 72.44 (6.11) years old and all lived
within the community. The StrTM, SSTM, and BSup CoV of the HA group
remained relatively unchanged throughout the study, while these same
measures of gait variability increased for the P group, with the greatest
increases observed at 6m. However, there were no signiﬁcant differences
between the HA and P groups regarding the CoV for StrTM [Mean difference
(95%CI)] [0.25 (0.70; - 0.20)], SSTM [0.48 (1.35; - 0.39)], or BSup [0.87 (6.77;
- 5.03)]. The HA group experienced greater reduction in WOMAC scores
than the P group, however, there were no signiﬁcant differences between
the HA and P groups regarding the WOMAC subsections of pain [2.27 (4.75;
- 0.22)], stiffness [0.80 (1.78; - 0.18)], and physical function [6.63 (14.35; -
1.10)].
Conclusions: The results of this small sample study demonstrate that
gait variability in knee OA patients was not reduced with intra-articular
HA treatment. However, the trends observed in the results indicate that
when compared to intra-articular P, intra-articular HA may maintain gait
function in knee OA patients by preventing further increases in gait vari-
ability, particularly in StrTM and SSTM variability. Since gait disturbances
are important risk factors for falling, these preliminary results provide
rationale for further investigation in a larger trial assessing the effect of
intra-articular HA on gait variability, and in reducing the risk of falling and
mobility decline in the elder knee OA population.
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A COMPARISON OF THE BENEFITS AND LIMITATIONS OF GUIDANCE BY
ULTRASOUND FOR INTRA-ARTICULAR HYALURONIC ACID INJECTIONS
FOR OSTEOARTHRITIS OF THE KNEE BETWEEN THE LATERAL AND
MEDIAL PATELLAR APPROACHES
Y. Toda, K. Keyaki
Toda Orthopedic Rheumatology Clinic, Osaka, Japan
Purpose: Although guidance for injections conducted by real-time ﬂuoro-
scopic imaging is useful to increase the accuracy rates of intra-articular
(IA) hyaluronic acid (HA) injections for osteoarthritis (OA) of the knee, this
imaging implies a certain dosage of radiation to the patient. Qvistgaard et
al (Osteoarthritis Cartilage. 2001) and Im et al (J Ultrasound Med. 2009)
reported the feasibility of guidance using ultrasound (US) for IA injections
in the knee through lateral and medial patellar approaches, respectively
(Figure 1). This study was designed to compare the accuracy rates and
visual analogue scale (VAS) for the highest subjective severe pain during
an injection by a orthopaedic surgeon who was beginner in the use of US
between the two approaches reported by Qvistgaard et al (Q) and Im et al
(I).
Figure 1
Methods: Eighty patients diagnosed with ‘dry’ knee OA with no clinically
detectable effusion received HA injections through the Q and I approaches.
A volume of 0.5-1 ml of asmospheric air was injected with simultaneous
recording of US signals on the B and M modes. Once IA positioning of the
needle was considered adequate, HA was injected and lateral radiographs
were taken 10 minutes later. Successful injections were conﬁrmed by a
sharply deﬁned shadow of air on the radiograph. A research nurse who was
blind to the objectives of the study asked the participants to assess the VAS
during injection, after each injection.
Results: The accuracy rates through I approach (78 out of 80, 97.5%)
were signiﬁcantly higher than those through Q approach (70 out of 80,
87.5%), (P=0.032). However, the VAS during injection through the Q ap-
proach (31.8±21.1%) was signiﬁcantly lower those through the I approach
(39.1±20.2%), (P=0.028).
Conclusions: In the Q approach, the straight surface of the US probe was
not ﬁt to the arc surface of thigh and the direction of the needle at the
insert site was unclear, so the accuracy rates were lower, compared with
those of the I approach. In the I approach, the needle punctured through
retinaculum tissue to reach the IA space and thus the VAS during the
injection was higher, compared with those of the Q approach.
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VISCOSUPPLEMENTATION FOR THE TREATMENT OF HIP OSTEOARTHRITIS
F. Rivera, C. Mariconda, C. Correggia, G. Annaratone
Presidio Sanitario Gradenigo, Torino, Italy
Purpose: Viscosupplementation is recognised as a valid treatment for
osteoarthritis and long-term results of hyaluronic acid inﬁltration therapy
reported in literature have encouraged the drug’s ever greater use in a
growing number of joints. The aim of our study was to determine the
eﬃcacy and safety of viscosupplementation with synthetic hyaluronic acid
to the hip joint.
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Methods: It has been set a prospective study to assess control pain and
functional performance in a group of patients affected by hip arthritis,
before and after viscosupplementation. From May 2005 to September 2009
we performed an intra articular inﬁltration into the hip of 207 patients
(108 male, 99 female), mean age 67,8 (range 40-83). Each patient re-
ceived under ﬂuoroscopic guidance one injection of highly puriﬁed sodium
hyaluronate derived from bacterial fermentation, containing 75 mg of
sodium hyaluronate per 3-ml syringe. The inclusion criteria were: hip pain,
radiographic evidence of arthritis with the articular rima at least partly
conserved, full range of motion of affected hip. All patients were evaluated
using BPI score, VAS score and Harris Hip score, pre-inﬁltration, after
three, six and twelve months after treatment. The categorical data were
summarized in terms of frequency and percentage. Continuous data where
analyzed in terms of mean, standard deviations, Student’s test. 150 patients
out of 207 were studied at six months follow-up, 121 patients out of 207
were studied at one year follow-up.
Results: Mean VAS scores before inﬁltration and at 1 year follow-up were
5.6 (range 10-6, SD 2,01) and 3.33 (range 10-3, SD 2.99) respectively
(p<0,05). Mean HHS were 44.2 (range 24-66, SD 10.4) and 76.5 (range
32-81, SD 16.4) respectively (p<0,05). Mean BPI Interference score were
27,38± (range 16-53, SD 17,68) and 14,35 (range 8-34, SD 12,60) respec-
tively (p<0,05). Fifty three patients (43%) reported at least 50% of pain
relief of pain at 6 months follow-up. Each item of BPI showed a decrease
of pain interference during daily activity. The decrease was statistically
signiﬁcant for all items (p<0,05). Particularly decreasing was observed for
pain interference with sleep (from 4,09, SD 3,15 pre inﬁltration to 1,27,
SD 1,36 at 1 year follow-up), mood (from 4,40, SD 3,17 pre inﬁltration to
2,04, SD 2,37 at 1 year follow-up), enjoy (from 3,21, SD 3,46 pre inﬁltration
to 1,27, SD 2,10 at 1 year follow-up). No local side effects or systemic
complications was observed in our series.
Conclusions: Our data show that viscosupplementation is a promising
approach for hip osteoarthritis, providing beneﬁcial effects in a long-term
follow up. The results demonstrated that it is possible to delay replacement
of the arthritic hip, but above all that hip pain could be eliminated in
patients clinically and radiographically at the limit of the indication for
surgical treatment.
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HYALURONIC ACID MANAGEMENT OF KNEE OSTEOARTHRITIS: IMPACT
ON PAIN
C. Taieb Sr.1, R. Dreiser Sr.2, J. Pibourdin Sr.3, N. Rahhali Jr.1
1PFSA, Boulogne Billancourt, France; 2Rhumatologist, Paris, France; 3PFS,
Castres, France
Purpose: Chronic pain or chronic pain syndrome is deﬁned as a mul-
tidimensional syndrome, when the pain expressed leads to a signiﬁcant
and progressive deterioration in the patient’s functional and relational
capacities. Knee osteoarthritis is a real public health problem. According to
data from the Framingham study, its prevalence is estimated to be 6.1% of
adults over the age of 30. This prevalence increases with age, to more than
40% after the age of 75. Knee osteoarthritis is generally not life-threatening,
but it does signiﬁcantly affect the daily lives of patients who have it and
incurs very high costs for the community
Methods: Pragmatic, longitudinal and prospective follow-up carried out
by rheumatologists in the context of their daily professional activities;
the investigator does not change the prescription or management habits.
The objective is to observe, under actual conditions of use, the pain
effect obtained, in the context of management of knee osteoarthritis, using
hyaluronic acid (injectable route).
Results: 191 patients are treated with hyaluronic acid. The average age is
64.72 years (±7.34). Average pain during activities of daily living (ADL) was
measured by means of a visual analogue scale (VAS). It is 50.12±19.32 at
inclusion.
At 6 months, this same average pain measured under the same conditions is
36.95±25.10. A third measurement at 12 months situates it at 38.10±23.19.
Pain during ADL is signiﬁcantly reduced between inclusion and month 6
(p=0.0023) and between inclusion and month 12 (p=0.0012).
With regard to pain measured at rest, it was also measured at inclusion,
at 6 and 12 months, by means of VAS. There is a signiﬁcant reduction in
pain at rest between inclusion and 6 months (p=0.0004) and the reduction
between inclusion and month 12 is also signiﬁcant (p=0.0007). At inclusion,
6 and 12 months, the average pain observed is 33.48±22.45, 19.90±19.88
and 21.64±22.94, respectively.
Conclusions: Our study, which assesses the effect on pain obtained in
the context of management of subjects with knee osteoarthritis, using
hyaluronic acid, showed a reduction in pain during ADL. This reduction
in pain, which is signiﬁcant at 6 months, then perpetuated at 12 months,
shows the relevance of the treatment protocol used by the doctors.
Therapy – Non-Pharmacologic
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EFFECTS OF ORAL ADMINISTRATION OF HYAL-JOINT® IN 17 DAY RAT
DEVELOPING TYPE II COLLAGEN ARTHRITIS
V. Castillo1, A.M. Bendele2, K. Li3, D. Martinez-Puig1 , S.M. Turner3,
C. Chetrit1
1BIOIBERICA S.A., PALAFOLLS, Spain; 2BolderPATH Inc., Boulder, CO; 3KineMed
Inc., Emeryville, CA
Purpose: To determine the effect of Hyal-Joint® administered by twice
daily oral dosing on inﬂammation, cartilage destruction, bone resorption
and synthesis of hyaluronic acid (HA) in synovial ﬂuid (SF) that occurs in
developing type II collagen arthritis in rats.
Methods: Twenty-four female Lewis rats weighing 136-154 g were used
in this study. Rats with developing type II collagen arthritis (n=20) were
treated orally twice daily on days 0-16 of the study with vehicle (H2O;
disease control; n=10) or Hyal-Joint® (7.5 mg, BID; n=10). They were
anesthesized with isoﬂurane and given collagen injection on day 0 and
6. Nonimmunized rats (normal; n=4) were used as normal controls. All
animals received deuterium oxide (2H2O) exposure from day 16-17 to bring
the animal’s body water to a 5% water isotopic enrichment of deuterium.
Animals were terminated on study day 17. Livers, spleen and thymus were
also collected, trimmed of extraneous tissue and weighed.
Eﬃcacy evaluation was based on animal body weights, ankle diameter
expressed as area under the curve (AUC), histopathologic evaluation of
ankles and knees. Isotopic analysis of lavage samples allowed to measure
SF volumes, HA concentration and absolute HA synthesis rate in knee SF.
Results: Body weight gain was signiﬁcantly increased toward normal
for rats treated with Hyal-Joint® (24% increase) as compared to disease
controls. Ankle diameter AUC were not signiﬁcantly reduced (14%; P=0.15)
for rats treated with Hyal-Joint® as compared to disease controls. Relative
liver, thymus and spleen weights for rats treated with Hyal-Joint® were
similar to those showed by normal rats (3.559 vs. 3.583 g, P=0.80; 0.239
vs. 0.222 g, P=0.146; and 0.199 vs. 0.220 g, P=0.191; respectively), which
conﬁrmed Hyal-Joint® safety. Individual ankle and knee histopathology
parameters (inﬂammation, pannus, cartilage destruction, bone resorption)
are showed in Figures 1 and 2, respectively. Summed histopathology scores
were signiﬁcantly reduced in ankle (17%, P < 0.05) and strongly reduced in
knee (51%,P<0.01) toward normal for rats Hyal-Joint® treated
as compared to disease controls.
Collagen-induced arthritis led to a signiﬁcant increase in knee synovial ﬂuid
volume in both vehicle and Hyal-Joint® treated rats, being less pronounced
in the second. HA concentration decreased 33% with disease controls, while
maintained similar to normal values in Hyal-Joint® group. In normal rats,
absolute synthesis rate of HA into the synovial ﬂuid was 0.43 μg/h. Disease
Figure 1
